News
DNLI
25.57
+3.40%
0.84
Denali Therapeutics (DNLI) Looks Fully Valued After $195 Million Voucher Sale
Simply Wall St · 4d ago
Why Denali Therapeutics (DNLI) Is Up 8.2% After Selling Its Priority Review Voucher For $195 Million
Simply Wall St · 5d ago
Weekly Report: what happened at DNLI last week (0615-0619)?
Weekly Report · 6d ago
Denali to sell priority review voucher for $195M
Seeking Alpha · 06/18 12:49
Denali Monetizes FDA Voucher to Advance CNS Pipeline
TipRanks · 06/18 12:36
Denali Monetizes FDA Voucher For $195M
NASDAQ · 06/18 12:25
Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV
TipRanks · 06/18 12:14
Denali Therapeutics Signs Deal To Sell Its Rare Pediatric Disease Priority Review Voucher For $195M
Benzinga · 06/18 12:07
Denali Therapeutics agrees to sell rare pediatric disease priority review voucher for USD 195 million
PUBT · 06/18 12:06
Denali Therapeutics to sell rare pediatric disease priority review voucher for $195 million
PUBT · 06/18 12:05
*Denali Therapeutics: FDA Awarded PRV Following Accelerated Approval of Enzyme Replacement Therapy AVLAYAH for Treatment of Hunter Syndrome in March >DNLI
Dow Jones · 06/18 12:02
*Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195M
Dow Jones · 06/18 12:01
DENALI THERAPEUTICS - TO SELL RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER FOR $195 MLN
Reuters · 06/18 12:00
Denali Therapeutics (DNLI) Receives a Buy from UBS
TipRanks · 06/16 12:36
Weekly Report: what happened at DNLI last week (0608-0612)?
Weekly Report · 06/15 09:17
Denali Therapeutics (DNLI) Stock Valuation After Setback In LUMA Trial And Focus On BEACON Study
Simply Wall St · 06/13 15:19
Should Denali’s Pivot to BEACON Precision Trial After BIIB122 Setback Require Action From Denali (DNLI) Investors?
Simply Wall St · 06/12 06:25
Weekly Report: what happened at DNLI last week (0601-0605)?
Weekly Report · 06/08 09:16
Denali Therapeutics Shareholders Back Board, Auditors, Executive Pay
TipRanks · 06/04 10:34
Denali Therapeutics shareholders elect three Class III directors at annual meeting
PUBT · 06/04 10:06
More
Webull provides a variety of real-time DNLI stock news. You can receive the latest news about Denali Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About DNLI
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.